Madrigal Retained Earnings vs Current Deferred Revenue Analysis
MDGL Stock | USD 205.13 2.91 1.40% |
Madrigal Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Madrigal Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Madrigal Pharmaceuticals is a good investment. Please check the relationship between Madrigal Pharmaceuticals Retained Earnings and its Current Deferred Revenue accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.
Retained Earnings vs Current Deferred Revenue
Retained Earnings vs Current Deferred Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Madrigal Pharmaceuticals Retained Earnings account and Current Deferred Revenue. At this time, the significance of the direction appears to have weak relationship.
The correlation between Madrigal Pharmaceuticals' Retained Earnings and Current Deferred Revenue is 0.32. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Madrigal Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Madrigal Pharmaceuticals' Retained Earnings and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of Madrigal Pharmaceuticals are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Retained Earnings i.e., Madrigal Pharmaceuticals' Retained Earnings and Current Deferred Revenue go up and down completely randomly.
Correlation Coefficient | 0.32 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Most indicators from Madrigal Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Madrigal Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.At this time, Madrigal Pharmaceuticals' Sales General And Administrative To Revenue is quite stable compared to the past year. Enterprise Value is expected to rise to about 4.6 B this year, although the value of Selling General Administrative will most likely fall to about 102.7 K.
Madrigal Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Madrigal Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Madrigal Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 442.1M | 287.0M | 273.3M | 362.6M | 640.5M | 672.6M | |
Total Stockholder Equity | 416.6M | 240.0M | 196.1M | 197.4M | 405.3M | 425.6M | |
Common Stock Shares Outstanding | 15.4M | 15.4M | 16.5M | 17.1M | 18.7M | 19.6M | |
Liabilities And Stockholders Equity | 442.1M | 287.0M | 273.3M | 362.6M | 640.5M | 672.6M | |
Other Stockholder Equity | 639.6M | 665.4M | 863.5M | 1.2B | 1.7B | 1.8B | |
Total Liab | 25.5M | 47.0M | 77.2M | 165.2M | 235.2M | 247.0M | |
Other Current Liab | 23.6M | 45.2M | 55.0M | 91.5M | 90.0M | 94.5M | |
Total Current Liabilities | 25.1M | 46.6M | 76.8M | 115.9M | 118.5M | 124.5M | |
Property Plant And Equipment Net | 1.9M | 1.8M | 1.6M | 1.2M | 3.3M | 2.1M | |
Net Debt | (46.0M) | (53.2M) | (35.5M) | (281.7M) | 17.3M | 18.1M | |
Retained Earnings | (223.2M) | (425.5M) | (667.3M) | (962.7M) | (1.3B) | (1.3B) | |
Accounts Payable | 1.2M | 1.0M | 21.4M | 23.8M | 28.0M | 29.4M | |
Cash | 46.7M | 54.0M | 36.3M | 331.5M | 99.9M | 99.8M | |
Non Current Assets Total | 1.9M | 1.8M | 1.6M | 1.2M | 3.3M | 2.4M | |
Non Currrent Assets Other | 1.9M | 1.8M | 797K | 1.2M | 1.4M | 719.9K | |
Cash And Short Term Investments | 439.0M | 284.1M | 270.3M | 358.8M | 634.1M | 665.8M | |
Short Term Investments | 392.3M | 230.1M | 234.1M | 27.2M | 534.2M | 560.9M | |
Other Current Assets | 1.2M | 1.0M | 1.3M | 2.6M | 3.2M | 3.3M | |
Property Plant And Equipment Gross | 1.9M | 1.8M | 1.6M | 1.2M | 3.3M | 2.1M | |
Total Current Assets | 440.2M | 285.2M | 271.7M | 361.4M | 637.3M | 669.1M | |
Accumulated Other Comprehensive Income | 216K | 47K | (80K) | (32K) | 468K | 491.4K | |
Non Current Liabilities Total | 361K | 468K | 387K | 49.3M | 116.7M | 122.5M | |
Net Tangible Assets | 416.6M | 240.0M | 196.1M | 197.4M | 227.0M | 184.4M | |
Retained Earnings Total Equity | (223.2M) | (425.5M) | (667.3M) | (962.7M) | (866.4M) | (823.1M) | |
Capital Surpluse | 639.6M | 665.4M | 863.5M | 1.2B | 1.3B | 1.4B | |
Property Plant Equipment | 1.2M | 1.0M | 1.6M | 601K | 691.2K | 734.4K | |
Net Invested Capital | 416.6M | 240.0M | 196.1M | 246.7M | 520.8M | 358.2M | |
Net Working Capital | 415.1M | 238.6M | 194.8M | 245.5M | 518.7M | 356.9M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.Note that the Madrigal Pharmaceuticals information on this page should be used as a complementary analysis to other Madrigal Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Complementary Tools for Madrigal Stock analysis
When running Madrigal Pharmaceuticals' price analysis, check to measure Madrigal Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Madrigal Pharmaceuticals is operating at the current time. Most of Madrigal Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Madrigal Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Madrigal Pharmaceuticals' price. Additionally, you may evaluate how the addition of Madrigal Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is Madrigal Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (19.98) | Return On Assets (0.40) | Return On Equity (0.89) |
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.